Volume dodolan perusahaan inflarx.de (IFRX)

Risks for InflaRx N.V. (IFRX) are linked to the instability of government contracts and a narrow sales market. However, the business relies on the macro-stability of R&D and the protection of intellectual property rights for antibodies. The company's sales profile demonstrates a support level where 0.00 serves as the base parameter value. This sales trend helps assess the actual scale of operations and avoid overpaying at peaks.

This indicator tracks daily revenue, assessing the ability of operating activities to generate incoming cash flows. By analyzing the commercial sales volumes of InflaRx N.V. (IFRX), an investor determines the effectiveness of the anti-C5a platform expansion and the pace of market capture within the immunopharma sector via B2B supplies to hospitals. Growth in this metric against a backdrop of falling liquidity signals risks of an asymmetric drawdown. A steady series of new highs confirms the fundamental resilience of the asset.